Crossmark

Cannabinoids and healthy ageing: the potential for extending healthspan and lifespan in preclinical models with an emphasis on Caenorhabditis elegans

Published Online: 2024-05-02

Authors

Wang, Zhizhen https://orcid.org/0000-0003-0511-8748
Arnold, Jonathon C. https://orcid.org/0000-0002-0159-9997
Funding

Funding for this research was provided by:

Lambert Initiative for Cannabinoid Therapeutics

University of Sydney
License Information

Text and Data Mining valid from 2024-05-02

Version of Record valid from 2024-05-02
More Information

Article History

Received: 12 December 2023

Accepted: 11 April 2024

First Online: 2 May 2024

Declarations

:

: JCA is Director of Preclinical Research at the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded research program at the University of Sydney. He has served as an expert witness in various medicolegal cases involving cannabis and has received consulting fees from the World Health Organisation (WHO), Medical Cannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiary of Glaxo Smith-Kline). He reports research grants from the Australian National Health and Medical Research Council (NHMRC) and from Lambert Initiative for Cannabinoid Therapeutics. He is an inventor on patents WO2019227167 and WO2019071302 issued, which relate to cannabinoid therapeutics. All other authors have no competing financial or non-financial interests to declare.

Document is current